risedronic acid has been researched along with Liver Cirrhosis in 2 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The groups had not only comparable Model for End-stage Liver Disease score and esophageal varices degree, but also similar incidence of digestive adverse effects." | 2.90 | Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial. ( Caramori, CA; Lima, TB; Nunes, HRC; Qi, X; Romeiro, FG; Santos, LAA; Silva, GF, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santos, LAA | 2 |
| Lima, TB | 2 |
| de Carvalho Nunes, HR | 1 |
| Qi, X | 2 |
| Romeiro, FG | 2 |
| Nunes, HRC | 1 |
| Silva, GF | 1 |
| Caramori, CA | 1 |
2 trials available for risedronic acid and Liver Cirrhosis
| Article | Year |
|---|---|
Two-year risedronate treatment for osteoporosis in patients with esophageal varices: a non-randomized clinical trial.
Topics: Bone Density; Bone Density Conservation Agents; Esophageal and Gastric Varices; Esophagitis; Gastroi | 2022 |
Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial.
Topics: Absorptiometry, Photon; Adult; Aged; Calcium; Esophageal and Gastric Varices; Female; Follow-Up Stud | 2019 |